Human graft-versus-host disease.
The principal clinical problem encountered following allogeneic bone marrow transplantation is acute and chronic graft-versus-host disease. The presence of acute graft-versus-host disease is the strongest predictor for the development of chronic graft-versus-host disease. The introduction of new prophylactic regimens has reduced the incidence of acute graft-versus-host disease. The clinical presentation and pathophysiology of acute and chronic graft-versus-host disease are discussed. New therapies for chronic graft-versus-host disease may result in improved treatment for human autoimmune diseases.
Parkman
R
R
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital of Los Angeles, California.
D016026:Bone Marrow Transplantation; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007121:Immunocompetence; D007945:Leukemia, Lymphoid / Q000276:immunology; D008727:Methotrexate / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D006680:HLA Antigens; D008727:Methotrexate